GT health — Wise Endocrine & Obesity Care

Patient MessagingPatients

  • Tzield: Preserving Insulin After Type 1 Diagnosis

    Tzield: Preserving Insulin After Type 1 Diagnosis

    Tzield offers eligible children with newly diagnosed type 1 diabetes an opportunity to preserve remaining insulin production. This article explains how teplizumab modifies immune activity, what the PROTECT trial established, and why insulin remains essential. Learn how age, timing, C-peptide testing, infusion schedules, and safety monitoring shape personalized decisions during the first weeks after diagnosis, alongside comprehensive support for children and their families throughout treatment.

    Categorized as , , ,